Articles

In a session during the 13th Annual Summit of the Association for Value-Based Cancer Care, held October 18-20, 2023, in New York City, Linde Wilson, MBA, Managing Partner, HealthQuest Advisors, discussed the ongoing challenges related to the development and implementation of value-based agreements.
Read More

Madrid, Spain—Results from 3 phase 3 clinical trials demonstrated the superiority of targeted therapies over conventional chemotherapy in patients with oncogene-addicted non–small cell lung cancer (NSCLC), including ALK-positive advanced NSCLC; EGFR exon 20 insertion-mutation–positive, newly diagnosed or advanced NSCLC; and advanced RET fusion–positive NSCLC. These findings were reported during the European Society for Medical Oncology Congress 2023.
Read More

On October 11, 2023, the FDA approved a new indication for encorafenib (Braftovi; Array BioPharma) combined with binimetinib (Mektovi; Array BioPharma) for adults with metastatic non–small cell lung cancer (NSCLC) and a BRAFV600E mutation, as detected by an FDA-approved test.
Read More

The 5th Annual Cholangiocarcinoma Summit, held October 19 to 21, 2023, in Scottsdale, AZ, brought together experts from around the world to discuss the latest research and clinical data pertaining to the diagnosis and treatment of patients with CCA and other biliary track cancers.
Read More

On October 20, 2023, the FDA accelerated the approval of the tyrosine kinase inhibitor entrectinib (Rozlytrek; Genentech) for the treatment of pediatric patients aged >1 month who are diagnosed with metastatic solid tumors associated with an NTRK gene fusion, as detected by an FDA-approved test, and no known acquired resistance mutation or whose disease is likely to lead to severe morbidity and has progressed after previous treatment, or patients who have no satisfactory standard therapy.
Read More

Supply channels are becoming more and more complex, and their models are evolving with an abundance of services to support both the providers and suppliers. Such complexity is causing both challenges and opportunities in this arena. What does the future hold?
Read More

Clinical trials have evolved over the years from gated phase 1, 2, and 3 approaches to more blended phase options and single-arm trials. However, we’re still seeing many of the same challenges, such as lack of patient access and diversity, similar or rising cost, and increasing complexity. Our panel of experts discussed the evolution of clinical trials and some unique solutions being considered for the future.
Read More

From the Pharmacy Benefits Manager (PBM) Reform Act and 340B Drug Pricing Program to drug shortages and the Inflation Reduction Act, this panel of Washington healthcare experts separated fact from fiction and noise from reality to provide a clear understanding for current legislative priorities.
Read More

Cancer treatments are advancing rapidly, thanks to the diligence of researchers and the foundations that support them. Panelists discussed emerging therapies, the impact of funding organizations, and what the future holds for the fight against cancers.
Read More

Artificial intelligence (AI) and machine learning (ML) platforms are becoming essential to the value equation in healthcare and to managing the complexity and range of treatment options within cancer care today. Panelists in this session explored the application of AI and ML technologies and their impact on care, outcomes, cost, providers, pharma, payers, and patients as well as their integrations between electronic medical records and future systems.
Read More

Page 2 of 338